TY - JOUR
T1 - Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score
T2 - results from the expanded international E-ALMA series (E-ALMA+)
AU - for the European ALMA + Investigators
AU - Falantes, José
AU - Pleyer, Lisa
AU - Thépot, Sylvain
AU - Almeida, António M.
AU - Maurillo, Luca
AU - Martínez-Robles, Violeta
AU - Stauder, Reinhard
AU - Itzykson, Raphael
AU - Pinto, Ricardo
AU - Venditti, Adriano
AU - Bargay, Joan
AU - Burgstaller, Sonja
AU - Martínez, María Pilar
AU - Seegers, Valerie
AU - Cortesão, Emilia
AU - Foncillas, María Ángeles
AU - Gardin, Claude
AU - Montesinos, Pau
AU - Musto, Pellegrino
AU - Fenaux, Pierre
AU - Greil, Richard
AU - Sanz, Miguel Angel
AU - Ramos, Fernando
PY - 2018/5/4
Y1 - 2018/5/4
N2 - Azacitidine (AZA) prolonged overall survival (OS) in the AZA-AML-001 trial. However, few subjects were randomized to AZA or intensive chemotherapy (IC). The Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) developed a score for older AML patients receiving IC or non-intensive regimens, whereas the E-ALMA study validated a score for survival and response in elderly patients receiving AZA in daily practice. Both identified three groups with different risk estimates. This analysis evaluates the efficacy of frontline AZA in older AML patients (N = 710) unfit for IC from different national registries (E-ALMA + series) stratified by the MRC/LRF risk score. Median OS of patients categorized as good, standard and poor-risk groups by the MRC/LRF score was 13.4 (95% CI, 10.8–16), 12.4 (95% CI, 9.9–14.8), and 8.1 months (95% CI, 7–9.1), respectively (p =.0001). In conclusion, this is the largest retrospective cohort of older AML patients treated with AZA.
AB - Azacitidine (AZA) prolonged overall survival (OS) in the AZA-AML-001 trial. However, few subjects were randomized to AZA or intensive chemotherapy (IC). The Medical Research Council (MRC) and the Leukemia Research Foundation (LRF) developed a score for older AML patients receiving IC or non-intensive regimens, whereas the E-ALMA study validated a score for survival and response in elderly patients receiving AZA in daily practice. Both identified three groups with different risk estimates. This analysis evaluates the efficacy of frontline AZA in older AML patients (N = 710) unfit for IC from different national registries (E-ALMA + series) stratified by the MRC/LRF risk score. Median OS of patients categorized as good, standard and poor-risk groups by the MRC/LRF score was 13.4 (95% CI, 10.8–16), 12.4 (95% CI, 9.9–14.8), and 8.1 months (95% CI, 7–9.1), respectively (p =.0001). In conclusion, this is the largest retrospective cohort of older AML patients treated with AZA.
KW - Acute myeloid leukemia
KW - Azacitidine
KW - E-ALMA+
KW - Elderly
KW - MRC/LRF risk score
UR - http://www.scopus.com/inward/record.url?scp=85028547438&partnerID=8YFLogxK
U2 - 10.1080/10428194.2017.1365854
DO - 10.1080/10428194.2017.1365854
M3 - Article
C2 - 28838276
AN - SCOPUS:85028547438
SN - 1042-8194
VL - 59
SP - 1113
EP - 1120
JO - Leukemia and Lymphoma
JF - Leukemia and Lymphoma
IS - 5
ER -
